Infinity Pharmaceuticals, Inc.
Present UC clinical data at ASCO GU
Delivered by the deadline
Under re-examination This entry has been challenged and is being re-checked against the sources.
- Announced
- 11 Feb 2021
- Due
- 28 Feb 2021
- Delivered
- 11 Feb 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“UC data at ASCO GU Feb ‘21”
What we found
Evidence strength A What the grades mean
The company presented clinical data from the MARIO-275 study in urothelial cancer patients at the ASCO GU symposium on February 11, 2021.
-
A Infinity Pharmaceuticals, Inc. 10-K filed 2021-03-16
“On February 11, 2021, we presented data at the American Society of Clinical Oncology Genitourinary Cancers Symposium, or ASCO GU, from MARIO-275... in checkpoint-naïve advanced urothelial cancer, or UC, patients” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Present
- Deliverable
- UC clinical data
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Infinity Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C113148-023568 · Corrections policy